my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
26-04-2012: Ablynx announced that Boehringer Ingelheim has submitted a Clinical Trials Application (CTA) to the European regulatory authorities to start a Phase I clinical trial with a Nanobody® for the treatment of Alzheimer's disease. The Nanobody has been developed as part of the collaboration signed between Ablynx and Boehringer and the event triggers a €1 million milestone payment to Ablynx.
In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies against a single disease target. The collaboration has a potential value of $265 million in upfront and milestone payments plus undisclosed royalties on product sales. Boehringer Ingelheim is solely responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Ablynx and Algeta enter into collaboration to evaluate Thorium-277 conjugated to nanobodies
Ablynx and Algeta ASA announce a research collaboration to evaluate a novel Targeted Thorium Conjugate (TTC) based on combining Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with Nanobodies® generated using Ablynx’s proprietary technology platform.Under the terms of the coll ... more
Ablynx proposes to strengten its board
Ablynx announced that Dr Roger Perlmutter and Dr Russell G. Greig will be proposed as Independent Non-Executive Directors at the Company's forthcoming Extraordinary General Meeting of its shareholders at the beginning of November 2012.Dr Perlmutter was Executive Vice President, Research an ... more
Ablynx's first inhaled nanobody successfully completes Phase I study
Ablynx announced that it has achieved positive results from a Phase I study with the first ever inhaled Nanobody, ALX-0171, a trivalent molecule which has been specifically designed by Ablynx for direct lung delivery, via a nebuliser, to treat respiratory syncytial virus (RSV) infections.Th ... more
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currentl ... more
Nanobody for Alzheimer's disease moves closer toward phase I clinical trial
Ablynx announced that Boehringer Ingelheim has submitted a Clinical Trials Application (CTA) to the European regulatory authorities to start a Phase I clinical trial with a Nanobody® for the treatment of Alzheimer's disease. The Nanobody has been developed as part of the collaboration sign ... more
Ablynx announces an extension of its global strategic nanobody alliance with Boehringer Ingelheim
Ablynx announced a two-year extension of the initial five-year research funding by Boehringer Ingelheim of their global strategic alliance to discover, develop and commercialise up to 10 different Nanobody® therapeutics. The extension which will run until September 2014, will allow all the ... more
Ablynx announced that Boehringer Ingelheim has selected, as part of their strategic alliance, a second Nanobody® candidate for pre-clinical development, which triggered a €5 million milestone payment to Ablynx. The Nanobody development candidate is designed to interfere with the function of ... more
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed f ... more
The Boehringer Ingelheim group of companies’ objectives and believes can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision. Together with our corporate culture concept "Lead & Learn", this vision is the driver of our corporate culture. A ... more
Boehringer Ingelheim Ellas A. E.
Boehringer Ingelheim's production site in Koropi, Greece produces solid forms, supplying European, Asian, African and Australian markets. Solid forms: * granulation * tabletting * tablet coating * capsule filling * blister packaging more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
